Puzzled by these neurological symptoms?

- Intractable epilepsy
- Movement disorders
- Developmental delays

...think **GLUT1DS**

METAglut1™

an innovative blood test to fight misdiagnosis and medical wandering at the earliest

The Glut1 Deficiency Syndrome (GLUT1DS or De Vivo Disease) is a rare neuro-metabolic disease caused by the impairment of glucose transporter 1 (GLUT1) that provokes glucose starvation of brain neurons

It is characterized by a **wide clinical variability** and affects more severely children who can suffer from **epilepsy, movement disorders and/or intellectual disabilities**

The correct **diagnosis is difficult to establish timely** and limitations in current diagnostic practice are responsible **for medical wandering with dramatic consequences, although a cure exists** (ketogenic diet)

CE IVD

METAglut1 is an in Vitro Diagnostic Medical Device used to aid in the diagnosis of the GLUT1 Deficiency Syndrome (GLUT1DS). It is a regulated health product that, under this regulation, bears the CE mark.

Because time matters

"It is essential to diagnose as early as possible to allow prompt compensation, through the Ketogenic Diet, for the brain's lack of fuel..."

"Early identification of children is important in order to avoid submitting them to possibly ineffective or potentially detrimental treatments with anticonvulsants" (1)

1/ *V. De Giorgis, P. Veggiotti / Seizure 22 (2013) 803–811 - GLUT1 deficiency syndrome 2013: Current state of the art.*

METAFORA

METAglut1 provides a **simple** way to find GLUT1DS patients **faster** and **accurately**

- **An underdiagnosed disease:** of estimated ca. 12,000 cases of GLUT1DS in EU and the USA, most remain undiagnosed [2]
- **Several complex symptoms** can be a clue of a GLUT1DS condition[3]:
  - Intractable epilepsy, in particular early onset absence epilepsy
  - Global developmental delay, particularly in speech
  - Complex movement disorders, paroxysmal events triggered by exercise



METAglut1™

an innovative test, made available for daily clinical use

(Published in Gras et al., Annals of Neurology 2017)

- A clear and actionable report to help you generate the right diagnosis at the right time
- Understand where your patients stand in the disease/ normal populations



Quick turnaround time (24-72hrs.)

A simple blood draw, no need for fasting

Accurate and affordable [4]

How to prescribe METAglut1™ in routine clinical practice?

- **Already available** in **France** and **Benelux** through Laboratoire Cerba
  www.lab-cerba.com

Benefits from an exceptional, fast track reimbursment in France through the *Forfait Innovation* Scheme

Soon in your country, send us an email:

- **metaglut1@metafora-biosystems.com**

About METAFORA

Metafora biosystems develops a platform for the discovery, development and distribution of blood tests that detect abnormalities in cellular energetics.
Using RBDs (Receptor Binding Domains), patented reagents that quantify cell nutrient transporters, coupled with powerful algorithms, the flow cytometry platform is able to detect abnormal nutrient consumption that may be the cause of illnesses such as neuro-metabolic diseases, cancer or inflammatory disorders.

METAglut1™ is supported by grant #806038 from the European Commission, within the Research and Innovation framework H2020.

METAFORA biosystems
Pépinière Paris Biotech Santé
29 rue du Faubourg Saint Jacques
75014 Paris • FRANCE

tel. +33 (0)9 61 62 65 17
contact@metafora-biosystems.com

www.metafora-biosystems.com

2/ *Pr Darryl De Vivo, Columbia Medical School, personal communication*
3/ *J. Klepper - Developmental Medicine & Child Neurology 2015, 57: 890–8*
4/ *Sensitivity = 77%, specificity > 99,5%*